^
    4years
    [VIRTUAL] CM-101 DEMONSTRATES REDUCTION IN SERUM FIBROTIC BIOMARKERS IN A PHASE 1b RANDOMIZED, CONTROLLED MULTIPLE DOSE TRIAL IN NAFLD PATIENTS (AASLD 2020)
    12 weeks treatment with CM-101 was safe and well tolerated. Although low disease burden patients recruited, repeated CM-101 administration showed early signals of anti-fibrotic activity by serum biomarkers and elastography. These advantages support CM-101 anti-fibrotic activity mediated by CCL24 blockage.
    Clinical • P1 data • Late-breaking abstract
    |
    CCL4 (Chemokine (C-C motif) ligand 4) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
    |
    CM101